LUA004 / Qilu Pharma - LARVOL DELTA

Preclinical characterization of LUA004, a novel 5T4-targeting ADC with improved therapeutic window (AACR 2026) - "LUA004 represents a novel 5T4-targeting ADC with favorable anti-tumor activity and superior tolerability, which can address the high unmet needs in patients with cancers expressing variable levels of 5T4. The promising preclinical profiles of LUA004 warrant its further development into clinical trials."

ADC • Preclinical • Lung Cancer • Oncology • Solid Tumor • TPBG